Text Size

Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT00610597
First received: January 28, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted

January 28, 2008
January 28, 2008
January 2005
January 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

Alcoholic liver disease is characterized by circulating T cell activation and liver T cell infiltration but their phenotype is poorly studied. The aim of the study is to test the hypothesis that the (CD4+ T cell secreting Interleukin-17) Th17 pathway is involved in alcoholic liver disease.

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver T cell infiltrates.
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

plasma and peripheral blood mononuclear cell culture medium.
Probability Sample

patients of Erasme University Hospital
  • Alcoholic Liver Disease
  • Chronic Hepatitis C Virus
Not Provided
  • 1
    alcoholic liver disease
  • 2
    chronic hepatitis C virus infection
Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009 Feb;49(2):646-57.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
January 2008
January 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Alcohol excess intake and suspected liver disease
  • Alcohol excess intake and clinical liver cirrhosis
  • chronic hepatitis C virus infection and suspected liver disease
  • chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria:

  • bacterial or fungal infection
  • immunosuppressive treatment
  • other causes of liver disease
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00610597
AL-ALD, AL-ALD
No
Olivier Le Moine, MD, PhD, Erasme University Hospital
Erasme University Hospital
Not Provided
Principal Investigator: Arnaud Lemmers, MD Erasme Hospital, Gastroenterology Dpt
Erasme University Hospital
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP